A recent workshop brought together global leaders in diabetes to assess existing approaches to disease heterogeneity and to identify research gaps, with a goal of achieving precision diabetology for all patients globally.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The potential of precision diabetology for type 2 diabetes treatment—evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trials
Acta Diabetologica Open Access 12 December 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Herder, C. & Roden, M. Diabetologia 65, 1770–1781 (2022).
Prasad, R. B. & Groop, L. J. Intern. Med. 285, 40–48 (2019).
National Institute of Diabetes and Digestive and Kidney Diseases. NIH https://go.nature.com/3ye5AZl (accessed 4 December 2023).
Chung, W. K. et al. Diabetologia 63, 1671–1693 (2020).
Tobias, D. K., Merino, J. & Ahmad, A. Nat. Med. 29, 2438–2457 (2023).
Acknowledgements
P.W.F. is supported by research grants from the European Commission (ERC-CoG_NASCENT-681742) and the Swedish Research Council (2014-03529 and 2019-01348). R.C.W.M. acknowledges support from the Research Grants Council of the Hong Kong Special Administrative Region (CU R4012-18). J.M.D. is a Wellcome Trust Early Career Award Fellow (227070/Z/23/Z) and acknowledges support from the National Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. S.M. is a Wellcome Trust Career Development Fellow (223024/Z/21/Z) and is supported by the NIHR Imperial Biomedical Research Centre. J.C.C. is supported by a Singapore Translational Research Investigator Award (NMRC/STaR/0028/2017) and the National Institute for Health and Care Research (NIHR132960). The views expressed are those of the authors and not necessarily those of the NIHR of the Department of Health and Social Care. M.S.U. acknowledges support from the Doris Duke Foundation (2022063), the NIDDK (K23_DK114551, R03 DK131249, U54_DK118612 and UM1_DK126185), National Human Genome Research Institute (U01_HG011723), Massachusetts General Hospital and Novo Nordisk. W.H.H.S. acknowledges support from the Research Grants from the National Health Research Institutes, Taiwan (MG-112-PP-18 and MG-113-GP-03). Relevant support for M.J.R. includes the US National Institutes of Health NIDDK grants R01DK124395 and R01DK121843. R.I.G.H. acknowledges support from the Southampton National Institute for Health Research Biomedical Research Centre. M.W. acknowledges support from the Canadian Institute of Health Research (DT4 179517), Diabetes Canada (OG-3-22-5681-MW), the Banting and Best Diabetes Centre and the Ajmera Family Chair. A.L.G. acknowledges support from the NIDDK (UM1 DK126185, U01DK123743, U24DK098085 and P30DK11607406) and the Wellcome Trust (095101 and 200837). M.R. and C.H. acknowledge support from grants to the German Diabetes Center by the German Federal Ministry of Health and the Ministry of Culture and Science of the state of North Rhine-Westphalia, from the European Community (HORIZON-HLTH-2022-STAYHLTH-02-01: Panel A) and the German Science Foundation (DFG). P.E.S. acknowledges support from the NIDDK (R01-DK55758, R01-DK99110 and R01-DK127274), as well as NIDDK-NORC P30-DK127984. J.C.F. acknowledges research support from the National Heart, Lung, and Blood Institute (K24 HL157960), the NIDDK (R01 DK123019.A1 and R01 DK132299), the National Institute of General Medical Sciences (R01 GM117163), the Doris Duke Foundation, the Medical University of Bialystok, Massachusetts General Hospital and Novo Nordisk. S.S.A. is supported by a Tier 1 Canada Research Chair in Ethnicity and CVD and a Heart & Stroke Foundation Chair in Population Health, and grants from the Canadian Institutes of Health Research. The planning and logistics of the global meeting and support services for this article were provided by W. Carpenter and S. Murray of The Hill Group, who provided contract services for the NIDDK. The group acknowledges the support of American Diabetes Association and European Association for the Study of Diabetes in providing meeting rooms for the discussions.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.W.F. was an employee of the Novo Nordisk Foundation at the time this Comment was written; the views expressed in this paper do not necessarily represent those of the Novo Nordisk Foundation, and the work performed was done in P.W.F.’s academic capacity. Over the past 5 years, P.W.F. has received consulting fees from Zoe, Lilly, Novo Nordisk; speaker fees from UBS; and investigator-initiated research grants from Lilly, Novo Nordisk, Boehringer Ingelheim and Servier. R.I.G.H. has received fees for lecturing from the European Association for the Study of Diabetes, Eli Lilly, Encore, Liberum, Novo Nordisk and ROVI and has received funding for conference attendance from Novo Nordisk and Eli Lilly. R.I.G.H. is chair of the European Association for the Study of Diabetes Committee for Clinical Affairs. A.L.G.’s spouse is an employee of Genentech and holds stock options in Roche. M.R. reports fees for lecturing and/or advisory board activities from Astra-Zeneca, Boehringer-Ingelheim Pharma, Echosens, Eli Lilly, Madrigal, MSD and Novo Nordisk, as well as fees for investigator-initiated studies from Boehringer-Ingelheim, Novo Nordisk and Nutricia/Danone. C.M. serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly, Novartis, Boehringer-Ingelheim, Roche, Medtronic, Imcyse, Insulet and Vertex; financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for C.M. from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics; and C.M. president of the European Association for the Study of Diabetes (all external support available at https://www.easd.org). F.G. has served as a research investigator for Eli Lilly and Roche Diabetes Care; has served as a speaker for AstraZeneca and Eli Lilly; has served as consultant for Abbott, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Medtronic, Merck Sharp & Dohme, Novo Nordisk, Roche Diabetes Care and Sanofi; and has received grants from Eli Lilly and Roche Diabetes Care. J.C.F. receives research support from Novo Nordisk for an investigator-initiated grant. J.S.T. serves on the scientific advisory boards of CytoReason, ImmunoScape and the Human Immunome Project. S.M. has received an investigator-initiated grant from Dexcom and has received speaker honoraria (for presentations over which she had complete control) from Eli Lilly and Sanofi, UK. S.S.A. has received speaking fees and consultancy work over the past 5 years from Bayer AG, Servier, Novartis and Novo Nordisk. W.T.C., N.A.Z., S.S.R., M.W., C.H., J.M.D. and D.G.M. declare no competing interests.
Rights and permissions
About this article
Cite this article
Cefalu, W.T., Franks, P.W., Rosenblum, N.D. et al. A global initiative to deliver precision health in diabetes. Nat Med 30, 1819–1822 (2024). https://doi.org/10.1038/s41591-024-03032-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-024-03032-4
